Loading…
Arrowhead Pharmaceuticals, Inc. is projected to rise to $128.04 by 2027, a +47% move from its current price of $87.32. ARWR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $84.72 | $87.42 | $90.20 | +0.11% |
| Aug 2 | $83.72 | $87.51 | $91.48 | +0.22% |
| Aug 3 | $82.98 | $87.61 | $92.49 | +0.33% |
| Aug 4 | $82.38 | $87.70 | $93.38 | +0.44% |
| Aug 5 | $81.86 | $87.80 | $94.17 | +0.55% |
| Aug 6 | $81.41 | $87.90 | $94.91 | +0.66% |
| Aug 7 | $81.00 | $87.99 | $95.60 | +0.77% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $81.00 | $87.99 | $95.60 | +0.77% |
| Week 2 | $78.87 | $88.67 | $99.70 | +1.55% |
| Week 3 | $77.41 | $89.36 | $103.15 | +2.34% |
| Week 4 | $76.30 | $90.05 | $106.28 | +3.13% |
| Week 5 | $75.40 | $90.75 | $109.22 | +3.92% |
| Week 6 | $74.65 | $91.45 | $112.03 | +4.73% |
| Week 7 | $74.01 | $92.15 | $114.75 | +5.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arrowhead Pharmaceuticals, Inc. operates in the healthcare sector as a company that develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials.
The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
ARWR is the healthcare stock Arrowhead Pharmaceuticals, Inc., currently priced at $88.70 with a market capitalization of $12.49B and a rank of 766. The current price sits within a bullish technical backdrop, and the long-range forecast points to meaningful upside over time. The 2026 forecast shows an average price of $88.70, with substantial upside projected in later years (e.g., $197.89 on average by 2030 and $1,611.93 by 2050).
These figures imply a strong, multi-year upward trajectory, though they are estimates and not guarantees.
Overall, the asset is positioned as a mid-cap healthcare stock with notable upside potential reflected in the year-by-year averages and max forecasts, but accompanied by high volatility as indicated by the 70% annualized volatility metric.
A major floor 35.6% below — a decisive break under it would weaken the trend.
The nearest floor, 18.3% below — buyers have tended to step in here.
Price is pressing into resistance (1.6% away) — a breakout level to watch.
A major ceiling 14.3% above — clearing it would confirm fresh momentum.
Key ARWR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARWR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $86.09 | Buy | $85.77 | Buy |
| MA 10 | $82.64 | Buy | $83.71 | Buy |
| MA 20 | $80.96 | Buy | $81.67 | Buy |
| MA 50 | $78.55 | Buy | $78.59 | Buy |
| MA 100 | $72.65 | Buy | $73.78 | Buy |
| MA 200 | $64.95 | Buy | $64.06 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.70 | Neutral |
| Stoch RSI (14) | 89.96 | Sell |
| CCI (20) | 68.77 | Neutral |
| Williams %R (14) | -7.97 | Info |
| MACD (12,26,9) | 0.99 | Buy |
| ROC (12) | 21.43 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 92.03 | Sell |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | 5.88 | Buy |
| Ultimate (7,14,28) | 74.58 | Sell |
| Momentum (10) | 15.94 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 87.48 | Sell |
| ADX (14) | 20.09 | Buy |
| ATR (14) | 2.13 | Info |
Near-term technical sentiment is BULLISH. The RSI(14) is 60, suggesting room to move higher without being overbought. The 50-day simple moving average sits at $77.50, above the 200-day SMA of $63.45, signaling a bullish trend in the intermediate term.
Support is at $70.73 and resistance at $88.70, with the 30-day price range spanning from $69.44 to $113.30. This chart setup indicates a constructive near-term path with potential for further upside toward the resistance level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $55.01 | $87.32 | $131.92 | 0% | Neutral | |
| $100.74 | $128.04 | $172.89 | +47% | Bullish | |
| $117.57 | $154.43 | $217.52 | +77% | Bullish | |
| $129.58 | $174.92 | $254.57 | +100% | Bullish | |
| $145.99 | $201.88 | $301.95 | +131% | Bullish | |
| $166.34 | $235.14 | $360.16 | +169% | Bullish | |
| $205.55 | $296.61 | $464.07 | +240% | Bullish | |
| $265.63 | $390.79 | $623.27 | +348% | Bullish | |
| $279.26 | $418.48 | $679.30 | +379% | Bullish | |
| $279.63 | $426.50 | $703.71 | +388% | Bullish | |
| $486.55 | $804.54 | $1,421.03 | +821% | Bullish | |
| $859.22 | $1,637.07 | $3,190.49 | +17.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $55.01 | $87.32 | $101.94 | +0.00% |
| August 2026 | $76.44 | $89.99 | $108.63 | +3.06% |
| September 2026 | $81.21 | $96.53 | $118.31 | +7.26% |
| October 2026 | $84.21 | $100.87 | $125.12 | +4.50% |
| November 2026 | $83.99 | $101.26 | $126.83 | +0.38% |
| December 2026 | $86.10 | $104.41 | $131.92 | +3.11% |
Click any year to see its month-by-month ARWR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ARWR price prediction for 2026 points to an average of $87.32 (low $55.01, high $131.92) — a potential gain of 0% on today's $87.32. A consolidation phase looks the most probable path here.
In 2027, ARWR is projected to trade between $100.74 and $172.89, averaging $128.04 — a potential gain of +47% from today's $87.32. That is up +47% on the projected 2026 average. Momentum favours further upside here.
Arrowhead Pharmaceuticals, Inc.'s 2028 outlook centres on $154.43, within a $117.57 to $217.52 range. That is up +21% on the projected 2027 average. That marks a +77% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ARWR could reach as high as $254.57, with a base case around $174.92 and support toward $129.58 — roughly +100% from $87.32. Momentum favours further upside here.
Expect ARWR to range from $145.99 to $301.95 through 2030. The $201.88 average target implies a +131% move from current prices. That is up +15% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ARWR price prediction for 2031 points to an average of $235.14 (low $166.34, high $360.16) — a potential gain of +169% on today's $87.32. Momentum favours further upside here.
In 2032, ARWR is projected to trade between $205.55 and $464.07, averaging $296.61 — a potential gain of +240% from today's $87.32. That is up +26% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Arrowhead Pharmaceuticals, Inc.'s 2033 outlook centres on $390.79, within a $265.63 to $623.27 range. That is up +32% on the projected 2032 average. That marks a +348% change versus current levels. Momentum favours further upside here.
By 2034, ARWR could reach as high as $679.30, with a base case around $418.48 and support toward $279.26 — roughly +379% from $87.32. Buyers look set to stay in control over this stretch.
Expect ARWR to range from $279.63 to $703.71 through 2035. The $426.50 average target implies a +388% move from current prices. That is up +2% on the projected 2034 average. Momentum favours further upside here.
The ARWR price prediction for 2040 points to an average of $804.54 (low $486.55, high $1,421.03) — a potential gain of +821% on today's $87.32. Buyers look set to stay in control over this stretch.
In 2050, ARWR is projected to trade between $859.22 and $3,190.49, averaging $1,637.07 — a potential gain of +17.7x from today's $87.32. That is up +103% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ARWR today (≈ 11.45213 ARWR) could be worth
$18,747.95
+$17,747.95 (+1775%) by 2050 · US Dollar
Based on the average projected ARWR price of $1,637.07 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARWRwould be worth at today's price.
$1,000 invested in ARWR on Jul 30, 2025 (≈ 63.673989 ARWR) would be worth
$5,560.01
+$4,560.01 (+456.0%) today · 5.56× · US Dollar
Based on a ARWR entry price of $15.7 vs. today's $87.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $86.78 | $1,006.22 | +0.6% |
| 1 month ago | $81.51 | $1,071.28 | +7.1% |
| 3 months ago | $74.81 | $1,167.22 | +16.7% |
| 6 months ago | $69.33 | $1,259.48 | +25.9% |
| 1 year ago | $15.7 | $5,560.01 | +456.0% |
| All time (5.0y) ago | $68.01 | $1,283.93 | +28.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARWR forecast.
Our base-case forecast reaches $170.00 around 2029.
Implied market cap at $170.00: $23.95B
The multi-year forecast shows a clear upside trajectory. In 2026, the average price is $88.70 with an ROI of 0 and a Neutral sentiment. By 2027 the average rises to $130.16 with an ROI of 46.7 and a Bullish tone, and by 2028 to $155.76 (ROI 75.6). In 2029 the average is $177.03 (ROI 99.6) and in 2030 it is $197.89 (ROI 123.1), both Bullish.
Looking further, 2031 shows $231.54 (ROI 161), 2032 $303.42 (ROI 242.1), 2033 $397.08 (ROI 347.7), 2034 $417.56 (ROI 370.8), and 2035 $422.84 (ROI 376.7), all Bullish. The horizon extends to 2040 with an average of $799.52 (ROI 801.4) and a max of $1,502.52, and to 2050 with an average of $1,611.93 (ROI 1717.3) and a max of $3,378.07, both Bullish. The forecast notes the asset experiences high volatility (annualizedVolatilityPct 70) across this period.
Tap a question to reveal the answer.
Average forecast price is $197.89 with an ROI of 123.1 and a Bullish sentiment.
Forecasts show a Bullish sentiment from 2027 onward with rising averages (e.g., $130.16 in 2027, $197.89 in 2030, up to $1,611.93 by 2050). The 2026 point is Neutral, indicating uncertainty in the near term.
Yes—2040 shows an average of $799.52 with a max of $1,502.52, and 2050 shows an average of $1,611.93 with a max of $3,378.07.
The 30-day range is from $69.44 to $113.30.
Current price is $88.70 and market capitalization is $12.49B.
Arrowhead Pharmaceuticals, Inc. Community Discussion
0Share your Arrowhead Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.